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Here we demonstrate that primary cultures of human fetal liver cells (HFLC) reliably sup-
port infection with laboratory strains of hepatitis C virus (HCV), although levels of virus
replication vary signiﬁcantly between different donor cell preparations and frequently
decline in a manner suggestive of active viral clearance. To investigate possible contribu-
tions of the interferon (IFN) system to control HCV infection in HFLC, we exploited the
well-characterized ability of paramyxovirus (PMV) V proteins to counteract both IFN
induction and antiviral signaling. The V proteins of measles virus (MV) and parainﬂuenza
virus 5 (PIV5) were introduced into HFLC using lentiviral vectors encoding a ﬂuorescent
reporter for visualization of HCV-infected cells. V protein-transduced HFLC supported
enhanced (10 to 100-fold) levels of HCV infection relative to untransduced or control vec-
tor-transduced HFLC. Infection was assessed by measurement of virus-driven luciferase, by
assays for infectious HCV and viral RNA, and by direct visualization of HCV-infected hepa-
tocytes. Live cell imaging between 48 and 119 hours postinfection demonstrated little or no
spread of infection in the absence of PMV V protein expression. In contrast, V protein-trans-
duced HFLC showed numerous HCV infection events. V protein expression efﬁciently
antagonized the HCV-inhibitory effects of added IFNs in HFLC. In addition, induction of
the type III IFN, IL29, following acute HCV infection was inhibited in V protein-trans-
duced cultures. Conclusion: These studies suggest that the cellular IFN response plays a sig-
niﬁcant role in limiting the spread of HCV infection in primary hepatocyte cultures.
Strategies aimed at dampening this response may be key to further development of robust
HCV culture systems, enabling studies of virus pathogenicity and the mechanisms by which
HCV spreads in its natural host cell population. (HEPATOLOGY 2011;54:1901-1912)
A
cute hepatitis C virus (HCV) infection in
humans frequently progresses to chronicity,1
and virus persistence in the liver has been sug-
gested to result, at least in part, from the ability of the
virus to antagonize the interferon (IFN) system.2-5 Par-
adoxically, our ability to culture the virus for pro-
longed periods in differentiated primary hepatocytes
in vitro has met with variable success.6-11
Use of the hepatoma line Huh-7 and its derivatives
and adaptation of viral genomes to propagation in
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these cells has made possible the generation of high
titer stocks of cell culture-derived HCV (HCVcc),12,13
enabling the identiﬁcation of cellular factors required
for virus entry and replication.14-18 It has become appa-
rent, however, that hepatoma lines may not fully reca-
pitulate all aspects of HCV replication in the liver, and
that host responses play an important part in determi-
nation of viral persistence or clearance. For example,
nucleotide polymorphisms in or near the gene for the
type III IFN, IL-28B, were recently shown to be predic-
tive of resolution of acute HCV infection, or favorable
response to IFN-alpha/ribavirin therapy in infected
patients.19 The profound effect of these host polymor-
phisms may suggest a weak point in HCV’s ability to
evade the innate or adaptive immune response.
In comparison to hepatoma lines, complex cultures
of primary human hepatocytes from genetically diverse
donors may provide a more informative environment
for studying the virus life cycle and cellular mecha-
nisms that may operate to limit virus spread. In the
present study we examined the efﬁciency of HCVcc
replication in primary human fetal liver cell cultures
(HFLC). To investigate the possible role of the innate
immune system in controlling productive HCV infec-
tion in these cultures we exploited the well-character-
ized ability of paramyxovirus (PMV) V proteins to
counteract both IFN induction20 and antiviral signal-
ing mediated by binding of the IFN receptor.21
All PMV genomes encode a unique open reading
frame termed V. Although diverse in overall amino
acid sequence (only 50% sequence identity between
PMV family members) all V proteins share a conserved
cysteine-rich C-terminus that interacts with the RNA
helicase domain of the pattern recognition receptors
(PRR) MDA5 and LGP2.22,23 In vitro, V proteins have
been shown to block induction of type I IFN in
response to stimuli that activate the MDA5 pathway.24,25
Evidence to date indicates that V proteins do not engage
or antagonize the related RNA helicase RIG-I.20,22
More extensively characterized is the ability of V
proteins to potently inhibit cytokine signaling path-
ways by targeting STAT (signal transducer and activa-
tion of transcription).21 Receptor engagement by type
I and type III IFNs results in the dimerization of
STAT1 and STAT2 and assembly of the transcription
complex ISGF3 that mediates expression of antiviral
genes.21,26,27 The STAT molecules targeted by V pro-
teins, and the mechanisms by which STAT signaling is
inhibited, vary greatly between different PMV family
members. The V protein of parainﬂuenza virus 5
(PIV5) targets STAT1 for proteosomal degradation by
recruitment and assembly of components of the cellu-
lar E3 ubiquitin ligase machinery.28,29 The V protein
of measles virus (MV) targets both STAT1 and STAT2
and prevents their nuclear translocation in response to
IFN receptor binding.30,31
We introduced the V proteins of PIV5 and MV
into cultured HFLC using bi-cistronic lentiviral vectors
encoding a ﬂuorescent reporter that permits direct vis-
ualization of HCV-infected cells.32 Our results show
that V protein expression signiﬁcantly enhances pro-
ductive infection of HFLC with HCVcc, protects these
cultures against the HCV-inhibitory effects of added
type I and type III IFNs and antagonizes the induction
of the type III IFN IL-29 in response to HCV infec-
tion. We also show by live-cell imaging that V protein
expression dramatically enhances the early spread of
HCV infection in these cultures.
Patients and Methods
Human Subjects. All protocols involving human
tissue were reviewed and exempted by the Rockefeller
University Institutional Review Board.
Isolation and Culture of HFLC. Deidentiﬁed fetal
livers (16-24 weeks gestation) were procured through
Advanced Bioscience Resources (ABR; Alameda, CA)
or the Human Fetal Tissue Repository of the Albert
Einstein College of Medicine (AECOM; New York,
NY). Livers received on ice were washed with hepato-
cyte wash buffer (HWB) consisting of Williams’ E
Medium (WEM) plus 10 mM HEPES, 50 lg/mL
gentamicin, 100 U/mL penicillin, and 100 lg/mL
streptomycin (Invitrogen). Tissue was minced then
resuspended in 20-40 mL warm digestion buffer con-
sisting of Hanks Balanced Salt Solution plus 40 mM
HEPES, 3.26 mM CaCl2, 2 U/mL DNase I Grade II
(Roche), and 0.2% Collagenase type IV (Sigma). Tis-
sue was digested for 30 minutes at 37C, then diluted
1:1 with HWB and gently pushed through 70 lm
cell-strainers (BD Biosciences). The suspension was
centrifuged at 100g for 3 minutes and the cell pellet
containing large hepatocytes was washed twice by
resuspension in 50 mL HWB and centrifugation at
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100g for 4 minutes. Hepatocytes were enriched by 1g
sedimentation in 25 mL HWB for 1 hour at room
temperature, followed by additional washing. In some
experiments hepatocytes were further enriched by cen-
trifugation through lymphocyte separation medium
(Cellgro, Manassas, VA) as described.33 Hepatocyte yields
ranged from 0.5 to 4  107 cells per tissue and cells
were generally >80% viable as assessed by Trypan blue
exclusion and collagen attachment. Hepatocytes were
plated at 1  105/cm2 on 24- or 48-well collagen
I-coated plates (BD Biosciences) in WEM containing
10% fetal bovine serum (FBS) (Omega Scientiﬁc, Tar-
zana, CA), 2 mM L-glutamine (Invitrogen), 1X ITS
Plus (BD Biosciences) and antibiotics. After overnight
incubation, adherent cells were washed with WEM, then
maintained in Hepatocyte Deﬁned Medium (HDM; BD
Biosciences) plus L-glutamine and antibiotics. The cul-
ture medium was aspirated and replaced every 2 days.
Lentiviral Vectors. V proteins and control protein
ﬁreﬂy luciferase (Fluc) were expressed from a hybrid
albumin promoter in a bi-cistronic lentiviral vector34
modiﬁed to express the HCV-dependent ﬂuorescence
relocalization (HDFR) cassette TagRFP-NLS-IPS.32 In
this cassette the ﬂuorescent reporter TagRFP is fused
to both a nuclear localization sequence (NLS) and the
transmembrane domain of the mitochondrially teth-
ered adapter protein IPS-1.32 Following HCV infec-
tion of HDFR-expressing cells, cleavage of IPS-1 by
the viral NS3-4A protease2 leads to migration of the
ﬂuorescent reporter from mitochondria to the nucleus,
enabling visualization of HCV-infected cells.32 Vector
construction and source of protein-coding sequences
are detailed in the Supporting Information and Sup-
porting Fig. S1A.
Transduction with Lentiviral Pseudoparticles
(PP). PP were prepared by cotransfection of 293T
cells with lentiviral and packaging plasmids as
described.15,32 HFLC were transduced 1-3 days postplat-
ing by incubation for 3-6 hours with PP stocks diluted
1:3 in HDM plus 20 mM HEPES and 4 lg/mL poly-
brene, then washed and fed with HDM.
HCVcc Inocula. HCVcc inocula used were the
Gaussia luciferase reporter virus Jc1FLAG2 (p7-
nsGluc2A)35 (JC1G) and J6JFH Clone 2,36 which
lacks a reporter but replicates to higher titer in Huh-
7.5 cells. Virus stocks were prepared by electroporation
of in vitro transcribed RNA into Huh-7.5 cells as
described35 and virus was collected in serum-free me-
dium, or medium containing 1.5 or 10% FBS. For
some experiments virus stocks were concentrated using
Amicon Ultracel-100K ﬁlters (Millipore). Infectious
titers of HCVcc inocula were determined by titration
on Huh-7.5 cells as described12 and are expressed as
50% tissue culture infectious doses (TCID50). HFLC
were infected for 3 to 6 hours with HCVcc diluted in
HDM, then washed and fed with HDM.
Detection of HCV RNA. Total RNA was extracted
from washed HFLC using RNEasy Kits (Qiagen).
HCV RNA was detected by quantitative RT-PCR
using the Eragen MultiCode-RTx method (Eragen
Biosciences, Madison, WI) and primers directed to the
50 untranslated region of the HCV genome. Quantita-
tion of HCV RNA copy number was achieved using a
synthetic RNA standard (Apath, Brooklyn, NY).
Cytokines and Drugs. Recombinant human cyto-
kines, IFN-beta (IFN-b), IL-28A, and IL-29, were
from Peprotech (Rocky Hill, NJ). The HCV NS5B
polymerase inhibitor 20 C-methyl adenosine (20CMA)
was the gift of D. Olsen and S. Carroll (Merck
Research Laboratories, West Point, PA).
Immunoﬂuorescence Analysis (IFA), Immunoblot-
ting, and Enzyme-Linked Immunosorbent Assay
(ELISA). IFA9 and immunoblotting14 were carried
out as described. Antibodies and reagents are detailed
in the Supporting Information. Human IL-29 was
detected using ELISA kits from eBioscience (San
Diego, CA). ELISA for human albumin is described in
the Supporting Information.
Time-Lapse Live Cell Imaging. HFLC were plated
on collagen-coated optical dishes and maintained in
HDM. Images were acquired on a Zeiss Axiovert-200
inverted microscope equipped with an environmental
chamber. Visualization of Tag-RFP in transduced
HFLC was achieved by laser excitation and emission
as described.32
Results
Cultured HFLC Are Long-Lived and Express HCV
Entry Factors. Like other investigators, we found
human fetal liver-derived hepatocytes to be long-lived
compared with cultured adult human hepatocytes.6,7,9
Figure 1A shows phase contrast morphology of cul-
tured HFLC. Hepatocytes formed a tightly packed
monolayer with refractive cell margins indicative of the
formation of canaliculi. Hepatocytes retained this mor-
phology and continued to secrete albumin for at least
1 month in culture (Fig. 1B).
At 16 to 24 weeks of gestation, human fetal liver is
considered to contain a mix of bi-potential hepatoblasts
(capable of forming both hepatocytes and cholangio-
cytes) and their more committed progeny. Figure 1C
shows IFA for the liver-derived proteins alpha-1 anti-
trypsin (AAT), alpha fetoprotein (AFP), and albumin,
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and for intermediate ﬁlament proteins in cultured
HFLC. Hepatocytes stained uniformly positive for albu-
min and AAT and unevenly for AFP. CK8 expression
was seen in both hepatocytes and cholangiocytes; the
latter were visible as frequent clusters of CK7-positive
cells within the hepatocyte monolayer. Unlike adult
hepatocytes, fetal liver epithelial cells commonly coex-
press mesenchymal markers such as vimentin in con-
junction with hepatocyte markers.38 As shown in Fig.
1C, cultured HFLC showed strong staining for vimen-
tin in cells with hepatocyte morphology and in cells
with ﬁbroblast morphology.
Fig. 1. Cultured HFLC are long-lived, express markers of differentiated hepatocytes, and are positive for the expression of HCV entry factors.
(A) Phase contrast microscopy of HFLC 2 weeks postplating. (B) Albumin secretion by HFLC during 1 month of culture (mean and SD of three
cultures). (C) Antibody staining for cytokeratin 8 (CK8), cytokeratin 7 (CK7), vimentin (Vim), alpha-1 antitrypsin (AAT), alpha fetoprotein (AFP),
and albumin (Alb) in cultured HFLC 1 week postplating. Bound antibody was detected with AlexaFluor (AF)-488-conjugated antibody to immuno-
globulins. (D) AF-488 (green) detection of bound antibodies to the tight junction protein zona occludens 1 (ZO1) and the HCV entry factors
occludin (OCLN) and claudin 1 (CLDN1) in cultured HFLC 1 week postplating. Hepatocyte staining for AAT (red) was detected with AF-594-conju-
gated antibody to goat IgG. Nuclei are counterstained with DAPI (blue). (E) Western blot for HCV entry factors in lysates of Huh-7.5 cells and
HFLC 1 week postplating: Lane 1, 15 lg Huh-7.5 lysate; Lane 2, 30 lg Huh-7.5; Lane 3, 30 lg HFLC. We also examined entry factor expres-
sion in HFLC transduced with each of the three lentiviral vectors described below. Lanes 4-6 correspond to 30 lg lysate from HFLC transduced
with pseudoparticles encoding: Lane 4, ﬁreﬂy luciferase; Lane 5, parainﬂuenza virus 5 V protein; Lane 6, measles virus V protein. Lysates were
prepared 6 days posttransduction. SRBI, scavenger receptor BI. Note that HFLC express the 60 kDa form of OCLN that is found in adult human
liver,37 and absent or weakly expressed in Huh-7.5 cells.
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CLDN1 and OCLN, two of the four known entry
factors for HCV, are tight junction proteins expressed
preferentially at the canalicular domain in adult
liver.16,17 In cultured HFLC, CLDN1, OCLN, and
the zona occludens marker ZO1 showed similar cana-
licular staining patterns (Fig. 1D). Immunoblot analy-
sis of all four HCV entry factors (CLDN1, OCLN,
SRBI, and CD81) in HFLC showed levels of expres-
sion comparable to those of the HCV-susceptible hep-
atoma Huh-7.5 (Fig. 1E). Taken together, these results
show that cultured HFLC, although immature in phe-
notype, express all of the entry factors required for
HCVcc infection.
Cultured HFLC Are Susceptible to Infection with
HCVcc. We ﬁrst tested the ability of cultured HFLC
to support productive infection with HCVcc using the
reporter virus JC1G, with Gaussia luciferase secretion
as the readout for infection. Figure 2A shows that
HFLC were susceptible to HCVcc infection and
secreted low but measurable levels of luciferase, which
persisted for at least 4 weeks of culture. Luciferase
secretion was reduced by addition of the polymerase
inhibitor 20CMA during the ﬁrst 6 days of culture,
demonstrating the signal to be dependent on HCV
RNA replication.
Figure 2C shows the results of an experiment in
which HFLC were infected with graded doses of JC1G
ranging from 104-107 TCID50. Establishment of detect-
able infection required virus doses >105 TCID50 per
culture (i.e., 1 TCID50 per seeded hepatocyte). Intri-
guingly, at all virus doses tested levels of secreted lucifer-
ase did not increase over time postinfection, but rather
persisted at levels similar to those achieved during the
ﬁrst 2 days after virus inoculation (Fig. 2B). We also
observed signiﬁcant donor-to-donor variability in both
the magnitude and duration of HCV replication
between HFLC infected with equivalent doses of the
same virus stock (Fig. 2C). In some experiments re-
porter virus replication declined in a manner suggestive
of active viral clearance (Fig. 2C, and see below).
These results are similar to those previously
obtained with HCVcc infection of micropatterned
adult human hepatocytes.9 They are in marked con-
trast to the exponential virus ampliﬁcation obtained
following HCVcc infection of Huh-7.5 cells.32 We
hypothesized that, despite the documented ability of
HCV to counteract innate antiviral sensing and signal-
ing pathways,2-5 spread of HCV infection in primary
HFLC may be limited by the IFN system. To investi-
gate this hypothesis we exploited the ability of PMV V
proteins to antagonize both IFN induction and IFN
signaling by way of STAT.
Fig. 2. Cultured HFLC are susceptible to infection with HCVcc. (A)
Gaussia luciferase secretion by HFLC (ABR-15168, 23 weeks gesta-
tion) following infection with the reporter virus JC1G in the presence or
absence of the polymerase inhibitor 20CMA (2.2 lm). Mock-infected
cells were incubated with culture medium alone. Polymerase inhibitor
treatment was discontinued after day 6 of culture. Secreted lucifer-
ase was measured at each medium change (mean and SD of three
cultures). RLU, relative light units. The dashed line indicates mean
plus 2 SD of RLU detected in culture medium alone. (B) Doses of
HCVcc required for establishment of detectable infection. HFLC
(AECOM-052810, gestational age not available) were incubated with
the indicated tissue culture infectious doses (TCID50) of JC1G for 5
hours, washed, and refed with HDM. Secreted luciferase was meas-
ured at each medium change (mean and SD of three cultures). (C)
JC1G infection of four different HFLC preparations with 105 TCID50
of a single virus stock that was prepared in medium containing 10%
v/v FBS.
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V Protein Expression Promotes Productive HCVcc
Infection in HFLC. We selected two PMV V proteins
that differ in their STAT targeting speciﬁcity and
mechanism of STAT inhibition. Expression of PIV5
and MV V proteins, and control protein Fluc, in
HFLC was achieved by transduction with lentiviral PP
encoding the HDFR cassette, which permits visualiza-
tion of HCV-infected cells by nuclear translocation of
RFP.32 Vector constructs and characterization of V
protein expression are described in the Supporting In-
formation and Supporting Fig. S1. Protein expression
was found to be efﬁcient in Huh-7 cells and hepato-
cytes (Supporting Fig. S1B-D), and vector transduc-
tion was found not to compromise HCV replication in
HFLC (Supporting Fig. S1E).
HFLC were either left untransduced or transduced
with PP 1-3 days postplating, then infected with
JC1G 4-6 days later. Figure 3A shows the effect of V
protein transduction in one experiment, using both
luciferase secretion (left panel) and infectious virus
production (right panel) as the readouts for infection.
Both luciferase secretion and virus release declined
steadily between days 2 and 12 postinfection in con-
trol cultures. In contrast, cultures transduced with
either PIV5 or MV V protein showed persistence of
luciferase and maintenance of virus production over
the same time period. Results from four independent
infection experiments are shown in Fig. 3B. In each
experiment, levels of infectious HCV recovered from
HFLC supernatants at 2 weeks postinoculation were
1-2 logs higher in V protein-transduced cultures
than control cultures. These results suggest that V pro-
tein expression serves to enhance productive infection,
or ‘‘rescue’’ an abortive infection with HCVcc in these
primary cells. Similar results were obtained in micro-
patterned cultures of adult human hepatocytes, indicat-
ing that the enhancing effects of V proteins on HCV
replication are not limited to fetal hepatocytes (see
Supporting Information and Supporting Fig. S2).
Direct Visualization of HCVcc Infection in Cul-
tured HFLC. We compared the effects of V protein
expression on replication of both JC1G and J6JFH
Clone 2, which replicates to comparatively higher
titers on Huh-7.5 cells.36 Figure 4A shows levels of
cell-associated HCV RNA detectable during the ﬁrst
96 hours postinfection with an equivalent dose of each
virus. In Fluc-transduced HFLC, levels of RNA for
both viruses declined slightly between 8 and 96 hours
postinfection. In V protein-transduced HFLC, HCV
RNA levels increased over the same time period, with
levels of J6JFH Clone 2 RNA increasing about
one log during the ﬁrst 24 hours. Figure 4C shows a
comparison of these two viruses using RFP nuclear
translocation32 as the readout for infection 7 days post-
inoculation. Nuclear translocation events were more
readily quantiﬁable for J6JFH Clone 2, particularly in
the context of V protein expression (Fig. 4B,C).
As with JC1G, V protein expression enhanced
J6JFH Clone 2 replication in HFLC, permitting sus-
tained, 20CMA-sensitive production of high titers of
infectious virus for 14 days (Fig. 5A). Scoring for RFP
translocation events during the ﬁrst 72 hours postin-
fection revealed a steady increase in the numbers of
HCV-infected cells in V protein-transduced HFLC,
but not in Fluc-transduced cultures (Fig. 5B).
The latter ﬁnding prompted us to carry out time-
lapse live cell imaging to monitor the appearance of
new RFP translocation events after HCVcc infection
(Fig. 6). The results showed little or no spread of
infection in Fluc-transduced cultures at 48-119 hours
postinfection, whereas V protein-transduced cultures
showed numerous new translocation events. Represen-
tative examples of 10 independent ﬁelds are shown for
each culture condition (Fig. 6). Video ﬁles are view-
able in the online version of the manuscript.
These results suggest that a major impact of V pro-
teins in HFLC is to promote virus spread during the
early stages of infection. V protein expression did not
measurably affect levels of HCV entry factors in HFLC
(Fig. 1E), or entry of HCV-enveloped PP (Supporting
Fig. S3), suggesting that their enhancing effect on infec-
tious HCV spread is not mediated at the level of virus
entry. We next tested which of the V proteins’ known
anti-IFN functions (i.e., inhibition of STAT signaling
and inhibition of IFN induction) were active in HFLC.
V Proteins Counteract the HCV-Inhibitory Effects
of Added IFNs in HFLC. Although they bind to dis-
tinct membrane receptors, both type I and type III
IFNs induce antiviral signaling by way of activation of
STAT1 and STAT2.26,27 We tested the ability of V
proteins to counteract the HCV-inhibitory effects of
IFN-b and type III IFNs, IL-28A, and IL-29 using the
JC1G reporter virus to measure productive infection
of HFLC (Fig. 7).
IFNs were added to the culture medium immedi-
ately after HCVcc infection and withdrawn after the
second day of culture. In control-vector-transduced
HFLC, all three IFNs inhibited HCV replication in a
dose-dependent manner, with maximal inhibition occur-
ring with 100 U/mL IFN-b, 100 ng/mL IL-28A, and
10 or 100 ng/mL IL-29 (Fig. 7A). With each dose of
each IFN the level of HCV replication in HFLC trans-
duced with PIV V protein was equivalent to that of cells
cultured in the absence of added cytokine, indicating
potent antagonism of STAT signaling and conﬁrming
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the efﬁciency of lentiviral transduction in these cultures.
HFLC transduced with MV V protein were likewise
protected, and for most IFN doses, luciferase levels were
equivalent to or greater than those of control cells cul-
tured without added cytokine (Fig. 7A).
To conﬁrm that the 2-day IFN dosing schedule
used was sufﬁcient to reduce productive HCV infec-
tion, we measured levels of infectious virus in HFLC
supernatants after 14 days of culture (i.e., 12 days after
removal of added IFN) (Fig. 7B). Infectious virus was
recovered from supernatants of V protein-transduced,
but not Fluc-transduced HFLC, treated with the maxi-
mally inhibitory doses of each IFN deﬁned above. In
addition, levels of HCV produced by HFLC cultured
without added cytokine were signiﬁcantly higher for V
protein-transduced cells (27-fold for MV V, and
15-fold for SV5) than control cells (Fig. 7B, left
panel). These data suggest that V protein expression
Fig. 3. PMV V protein expression enhances productive infection with JC1G in cultured HFLC. (A) One day postplating, HFLC (ABR-5591, 17
weeks gestation) were transduced with lentiviral vectors encoding ﬁreﬂy luciferase (Fluc), parainﬂuenza virus 5 V protein (PIV5 V), or measles vi-
rus V protein (MV V), or left nontransduced (NTD). Five days later cells were infected with 1  106 tissue culture infectious doses (TCID50) JC1G
reporter virus. Washed cells were cultured in HDM and the medium was removed and replaced every 2 days. Harvested supernatants were
assayed for luciferase (left panel) and for levels of infectious virus by titration on Huh-7.5 cells (right panel). RLU, relative light units. Values
show mean and SD of three cultures. The dashed line indicates the lower limit of detection for each assay. (B) Levels of infectious virus recov-
ered from cell supernatants 2 weeks post-JC1G infection of four different HFLC preparations. Graphs show mean and SD of 2-4 cultures. Log-
transformed TCID50 values within each experiment were analyzed by 1-way analysis of variance (ANOVA) with Bonferroni multiple comparison
posttest. Values that differ signiﬁcantly from both nontransduced (NTD) and Fluc-transduced cultures are indicated: *P < 0.05; **P < 0.01;
***P < 0.001. Fold differences relative to nontransduced cultures are summarized below the graphs.
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counteracts the inhibitory effects of added IFN and
also antagonizes endogenous cytokines generated dur-
ing the course of infection.
V Protein Expression Inhibits IL-29 Protein
Induction in HCVcc-Infected HFLC. In the accompa-
nying article we report that acute infection of HFLC
with J6JFH Clone 2 results in the secretion of IL-29
into the culture supernatant and induction of mRNAs
for IL-29 and IL-28B.39 Detectable induction of type
III IFNs was less frequent in HFLC infected with the
JC1G reporter virus, possibly reﬂecting the superior
replication efﬁciency of J6JFH Clone 2 relative to
JC1G.
In light of these results, we determined whether
PMV V protein expression would modulate IL-29
induction after acute infection of HFLC with J6JFH
Clone 2. As shown in Fig. 8, both untransduced and
control transduced HFLC showed a peak of IL-29
production at 48 hours postinfection with HCVcc,
which declined by 72 hours. No detectable IL-29 pro-
duction was seen in mock-infected HFLC (assay cutoff
50 ng/mL). In HFLC transduced with either PIV5 or
MV V proteins, little or no IL-29 induction was seen
at any timepoint postinfection with HCVcc.
Discussion
We have shown that primary cultures of HFLC reli-
ably support productive infection with HCVcc. Virus
replication was sensitive to inhibition by the polymerase
Fig. 4. J6JFH Clone 2 replicates to higher levels in HFLC than JC1G, and replication is enhanced by V protein expression. Four days posttrans-
duction with lentiviral vectors, HFLC (AECOM-063010; gestational age not available) were incubated with 1  107 TCID50 JC1G or J6JFH Clone 2
for 6 hours, washed three times, and cultured in HDM. (A) Levels of cell-associated HCV RNA detected during the ﬁrst 4 days postinfection
(mean and SD of 2 assays on 2 cultures). (B) Representative images for HFLC infected with J6JFH Clone 2. (C) Numbers of RFP-positive nuclei
per microscope ﬁeld on day 7 postinfection (mean and SD of six ﬁelds from two cultures).
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inhibitor 20CMA (Figs. 2A, 5A), and to added IFNs
(Fig. 7). Levels of virus replication varied signiﬁcantly
between different donor cell preparations and frequently
declined in a manner suggestive of active viral clearance
(Figs. 2, 3). At present, we do not know whether this
variability is due to differences in cellular composition
or state of differentiation of hepatocytes within these
cultures or to genetic differences between tissue donors.
Studies to date have not revealed an association with
IL28B genotype.39
V protein-transduced HFLC supported signiﬁcantly
enhanced (10 to 100-fold) levels of HCV infection
relative to untransduced or control vector-transduced
HFLC. Infection was assessed by measurement of
virus-driven luciferase, by assays for infectious HCV and
viral RNA, and by direct visualization of HCV-infected
hepatocytes (Figs. 3-5). Similar results were obtained
with micropatterned cocultures of adult human hepato-
cytes11 (Supporting Fig. S2).
Time-lapse live cell imaging of HFLC 48-119 hours
postinfection demonstrated little or no spread of infec-
tion in the absence of V protein expression. In contrast,
V protein-transduced HFLC showed numerous HCV
infection events (Fig. 6). To our knowledge, this is the
ﬁrst report of visualization of HCV spread in primary
cells. During the course of live cell imaging we observed
considerable turnover of HCV-infected cells. Cell turn-
over could indicate a direct cytopathic effect of HCV
infection in primary hepatocytes. However, more com-
prehensive studies will be required to determine the sur-
vival time of HCV-infected cells relative to uninfected
hepatocytes in these cultures.
V proteins did not measurably affect levels of
expression of HCV entry factors in HFLC (Fig. 1),
nor did they function to promote virus entry as
assessed by experiments using HCV-enveloped pseudo-
particles (Supporting Fig. S3), or measurements of
cell-associated HCV RNA 8 hours postinfection (Fig.
4A). Taken together, these results suggest that V pro-
teins exert their effect by mechanisms independent of
an effect on virus entry. Consistent with their known
role in counteracting innate immunity during PMV
Fig. 5. Kinetics of J6JFH Clone 2 replication in cultured HFLC. (A) Five days posttransduction, HFLC (AECOM-031010, gestational age unavailable)
were incubated with 1  107 TCID50 J6JFH Clone 2, washed three times, and refed with HDM with or without of 2.2 lm 20CMA. Cells were washed again
and refed 24 hours postinfection. Treatment with 20CMA was discontinued on day 7. Infectious virus in culture supernatants was determined by titration
on Huh-7.5 cells. Values are mean and SD of four cultures. (B) Kinetics of appearance of RFP-positive nuclei during the ﬁrst 3 days of culture following
infection with J6JFH Clone 2 (ABR-8338; 20 weeks gestation). Values are mean and SD of nuclei counts from four ﬁelds of two cultures.
Fig. 6. Live-cell imaging of J6JFH Clone 2 infection in PMV V protein- or Fluc-transduced HFLC. Five days posttransduction with lentiviral vec-
tors, HFLC (ABR-3676; 19 weeks gestation) were infected with 1  107 TCID50 J6JFH Clone 2. Washed cells were cultured in HDM for 48 hours
prior to initiation of imaging. For each culture condition, 10 ﬁelds containing at least one cell with nuclear translocation of RFP were selected to
monitor possible spread of infection. The ﬁgure shows the ﬁrst frame of representative ﬁelds of cells transduced with (A). Fireﬂy luciferase (Fluc).
(B) Parainﬂuenza virus 5 V protein (PIV5 V) or (C) measles virus V protein (MV V). Full videos for each ﬁeld are shown in Fig. 6A_Fluc.avi, Fig.
6B_PIV5 V.avi, and Fig. 6C_MV V.avi and are viewable in the online version of the manuscript. The time stamp indicates elapsed time in hours
beginning at 48 hours postinfection.
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infection, we found V protein expression to efﬁciently
antagonize the HCV-inhibitory effects of added IFNs
in HFLC (Fig. 7).
Interestingly, induction of the type III IFN, IL-29,
that follows acute HCVcc infection of HFLC39 was
inhibited in V protein-transduced cultures (Fig. 8).
Fig. 7. V protein expression counteracts the HCV-inhibitory effects of added type I and type III interferons in HFLC. Four days posttransduction
with lentiviral vectors, HFLC (ABR-1108; 19 weeks gestation) were incubated with 1  106 TCID50 per well JC1G reporter virus for 5 hours. Cells
were washed three times then refed with HDM containing serial 10-fold dilutions of IFN-b, IL-28A, or IL-29. The culture medium was aspirated
and replaced every 2 days. Cytokine treatment was discontinued after the second day of culture. (A) JC1G reporter virus-derived luciferase activ-
ity detected in culture supernatants during the ﬁrst 6 days of culture (mean and SD of two cultures). RLU, relative light units. (B) Levels of infec-
tious HCV detected in cell culture supernatants on day 14 of culture (mean and SD of two assays on two cultures). TCID50, tissue culture
infectious doses; Fluc, ﬁreﬂy luciferase; PIV5 V, parainﬂuenza virus 5 V protein; MV V, measles virus V protein.
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Studies conducted predominantly in hepatoma lines
have deﬁned RIG-I as the primary PRR required for
IFN induction after HCV infection.5 Because V pro-
teins do not engage RIG-I, but do bind helicases
MDA5 and LGP2,20,22 our results may suggest that
recognition of HCV RNA occurs differently in
primary HFLC cultures, and that infection of these
cells leads to the generation of RNA species that are
capable of directly activating the MDA5 pathway.
Alternatively, they may reﬂect V protein antagonism
of the PRR up-regulation that has been shown to
accompany IFN stimulation.40 Previous work from
our laboratory has shown that overexpression of RIG-I
or MDA5 is inhibitory for HCV replication in Huh-7
cells.34 Additional studies are required to further deﬁne
the mechanisms for V protein-mediated enhancement
of HCV replication in primary culture.
Chimeric HCV genomes, such as those used in
our study, enable the production of well-deﬁned
virus stocks for use in infection experiments. In con-
trast, HCV derived from patient plasma or tissues
may be of variable infectious titer, and frequently
complexed with virus-neutralizing antibody. Reports
of successful infection of primary hepatocytes with
such isolates are relatively rare, and the degree of
replication achieved has varied widely between differ-
ent culture systems.6-11 Few have reported sustained
production of titratable infectious virus. Many
factors may contribute to this variability, including
the differentiation state of cultured hepatocytes and
differences between HCV genomes in their relative
dependence on cellular cofactors required for virus
replication and spread.
Our results with HCVcc suggest that the hepatocyte
innate response to infection may provide an additional
barrier to productive replication in primary culture.
Strategies aimed at dampening this response may be
key to the further development of robust HCV culture
systems based on infection or transfection of viral
genomes.
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